KR102120005B1 - A composition having anti-oxidation or anti-bacterial activity comprising Glehnia littoralis extracts - Google Patents
A composition having anti-oxidation or anti-bacterial activity comprising Glehnia littoralis extracts Download PDFInfo
- Publication number
- KR102120005B1 KR102120005B1 KR1020190046775A KR20190046775A KR102120005B1 KR 102120005 B1 KR102120005 B1 KR 102120005B1 KR 1020190046775 A KR1020190046775 A KR 1020190046775A KR 20190046775 A KR20190046775 A KR 20190046775A KR 102120005 B1 KR102120005 B1 KR 102120005B1
- Authority
- KR
- South Korea
- Prior art keywords
- ethyl acetate
- antioxidant
- gaetbangpung
- acetate fraction
- activity
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 230000000844 anti-bacterial effect Effects 0.000 title abstract description 13
- 239000000284 extract Substances 0.000 title abstract description 5
- 244000146486 Glehnia littoralis Species 0.000 title abstract description 4
- 235000004036 Glehnia littoralis Nutrition 0.000 title abstract description 4
- 230000003064 anti-oxidating effect Effects 0.000 title 1
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 35
- BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000002038 ethyl acetate fraction Substances 0.000 claims abstract description 25
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 24
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 24
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 22
- OIUBYZLTFSLSBY-HMGRVEAOSA-N quercetin 4'-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)C=C1O OIUBYZLTFSLSBY-HMGRVEAOSA-N 0.000 claims abstract description 19
- YDDUMTOHNYZQPO-UHFFFAOYSA-N 1,3-bis{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid Natural products OC1C(O)CC(C(O)=O)(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-UHFFFAOYSA-N 0.000 claims abstract description 11
- SITQVDJAXQSXSA-CEZRHVESSA-N Cynarin Natural products O[C@@H]1C[C@@](C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)(OC(=O)C=Cc3cccc(O)c3O)C(=O)O SITQVDJAXQSXSA-CEZRHVESSA-N 0.000 claims abstract description 11
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 claims abstract description 11
- YDDUMTOHNYZQPO-BKUKFAEQSA-N cynarine Natural products O[C@H]1C[C@@](C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O YDDUMTOHNYZQPO-BKUKFAEQSA-N 0.000 claims abstract description 11
- 229950009125 cynarine Drugs 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 19
- 235000013305 food Nutrition 0.000 claims description 14
- 241000193468 Clostridium perfringens Species 0.000 claims description 12
- 241000589877 Campylobacter coli Species 0.000 claims description 9
- 241000193755 Bacillus cereus Species 0.000 claims description 8
- 241000186779 Listeria monocytogenes Species 0.000 claims description 8
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 8
- 229930003935 flavonoid Natural products 0.000 claims description 8
- 150000002215 flavonoids Chemical class 0.000 claims description 8
- 235000017173 flavonoids Nutrition 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 241000589875 Campylobacter jejuni Species 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 230000002292 Radical scavenging effect Effects 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 5
- 235000013824 polyphenols Nutrition 0.000 claims description 5
- 241000607272 Vibrio parahaemolyticus Species 0.000 claims description 4
- 241000186781 Listeria Species 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 claims description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims 1
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 claims 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims 1
- 235000008777 kaempferol Nutrition 0.000 claims 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 abstract description 10
- BITPRCODIALMOV-UHFFFAOYSA-N Kaempferol-3-diglucosid Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 BITPRCODIALMOV-UHFFFAOYSA-N 0.000 abstract description 8
- RTATXGUCZHCSNG-QHWHWDPRSA-N Nicotiflorin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-QHWHWDPRSA-N 0.000 abstract description 8
- RTATXGUCZHCSNG-UHFFFAOYSA-N nicotiflorine Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-UHFFFAOYSA-N 0.000 abstract description 8
- 239000004599 antimicrobial Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 11
- 206010016952 Food poisoning Diseases 0.000 description 9
- 208000019331 Foodborne disease Diseases 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- -1 reducing metabolism Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940093499 ethyl acetate Drugs 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 238000002828 disc diffusion antibiotic sensitivity testing Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000007845 reactive nitrogen species Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241001660259 Cereus <cactus> Species 0.000 description 1
- 241001327126 Clostridium perfringens C Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-MVHIGOERSA-N D-ascorbic acid Chemical compound OC[C@@H](O)[C@@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-MVHIGOERSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3472—Compounds of undetermined constitution obtained from animals or plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 갯방풍 잎 에탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 포함하는 항균 및 항산화 조성물에 관한 것이다.The present invention relates to an antimicrobial and antioxidant composition comprising an ethyl acetate fraction of ethanol extract of Gaetbangpung leaf as an active ingredient.
산소는 생명유지를 위한 여러 대사반응에 필수요소이고, 인체 내 독극물질 해독을 위해서도 필요하지만 산소가 인체에 유익한 것만은 아니어서 체내 효소계, 환원대사, 화학약품, 광화학반응 등 각종 공해물질, 물리 화학적, 환경적 요인 등에 의해 수퍼옥사이드 라디칼(superoxide radical), 하이드록시 라디칼(hydroxyl radical), 과산화수소(hydrogen peroxide), 일중항산소(singlet oxygen)와 같은 반응성이 매우 큰 자유라디칼(free radical)로 전환되면 생체에 치명적인 산소독성을 일으키는 양면성이 있다(Korea J. Biotechnol . Bioeng ., 2001, 16(6), 592-602). 이러한 활성산소를 제거하기 위한 합성 항산화제인 BHT (butylated hydroxy toluene)와 BHA (butylated hydroxy anisole) 등은 탁월한 항산화 효과와 경제성 때문에 지금까지 널리 사용되어 왔으나 간 비대, 체내 흡수물질의 독성화 및 발암 가능성 등의 문제가 제기되어 허용대상 식품이나 사용량이 엄격히 제한되고 있다. Oxygen is an essential element in various metabolic reactions to maintain life, and it is also necessary for detoxifying poisons in the human body, but oxygen is not only beneficial to the human body, so various pollutants such as enzymes, reducing metabolism, chemicals, and photochemical reactions in the body, and physical and chemical When it is converted into free radicals with very high reactivity such as superoxide radical, hydroxyl radical, hydrogen peroxide, and singlet oxygen due to environmental factors, etc. It has a double-sided effect that causes fatal oxygen toxicity in the body ( Korea J. Biotechnol . Bioeng . , 2001, 16(6), 592-602). Synthetic antioxidants such as BHT (butylated hydroxy toluene) and BHA (butylated hydroxy anisole), which are synthetic antioxidants for removing these free radicals, have been widely used so far due to their excellent antioxidant effect and economic efficiency. Due to the issue of, the allowed food or consumption is strictly limited.
또한, 식품, 화장품, 섬유 및 의약품 등의 제품은 품질을 오랫동안 유지하기 위해서, 미생물에 의한 부패를 막아주는 방부제가 필수적이며, 특히 제품 특성상 유통기간이 비교적 길며 미생물 영양원이 많은 화장품의 경우는 더욱 방부제가 요구된다. 최근 '옥시 사건'을 통해 제기된 바와 같이 합성 원료의 경제성에 비해 위험요소는 항상 잠재해 있으며, 단순한 산술적 통계에 따른 이윤만을 평가하기에는 위험요소가 현실화되었을 때 야기되는 문제는 치명적이라고 할 수 있다. In addition, in order to maintain the quality of products such as food, cosmetics, textiles, and medicines for a long time, a preservative to prevent spoilage by microorganisms is essential, and especially in cosmetics, the shelf life is relatively long and in the case of cosmetics with many microbial nutrients, the preservative is more Is required. The risk factor is always latent compared to the economics of synthetic raw materials, as raised through the recent'oxygen incident', and the problem caused when the risk factor is realized is fatal to evaluate profits based on simple arithmetic statistics.
기존의 방부제로서 화장품, 식품 및 의약품 등에 가장 범용적으로 사용되는 파라벤류의 방부제들은 피부 알러지 및 내성균 유발이라는 문제점이 제시되고 있으며, 이러한 문제점을 해결하고자 제품의 안전성과 경제성이 우수한 천연방부제에 대한 연구가 지속되고 있다. 천연 보존제(방부제)란 식품, 화장품 중의 장기보존 및 유통기한 연장을 위해 사용되는 첨가물로서 미생물에 의한 부패 방지에 사용되는 생물유래 소재를 의미하며, 화학 합성 보존제는 지속적인 사용 시 위해성으로 인해 사용량과 이용범위를 엄격하게 제한하고 있는 실정임에도 불구하고 만성 및 급성 독성, 돌연변이, 발암 등 다양한 부작용의 우려가 끊임없이 제기되고 있다. As a conventional preservative, paraben-based preservatives, which are most commonly used in cosmetics, food, and pharmaceuticals, have been suggested to cause skin allergies and resistant bacteria. To solve these problems, research on natural preservatives with excellent product safety and economic efficiency Is going on. Natural preservatives (preservatives) are additives used for long-term preservation and extended shelf life in food and cosmetics, and refer to bio-derived materials used to prevent spoilage by microorganisms, and chemical synthetic preservatives are used and used due to the risk of continuous use. Despite the fact that the scope is strictly limited, there are constant concerns about various side effects such as chronic and acute toxicity, mutation, and carcinogenesis.
한편, 갯방풍(Glehnia littoralis Fr. Schm.)은 산형과(Umbelliferae)에 속하는 여러해살이 풀로 우리나라 해안가 모래땅에 자생하며 일본, 만주, 중국 등지에 분포하는 약용식물이다. 그 뿌리를 북사삼(北沙蔘), 빈방풍(濱防風) 또는 해방풍(海防風)이라 부르며 양음(養陰), 청폐(淸肺), 거담(祛痰), 지해(止咳)의 효능이 있어 전통적으로 항염증, 진해거담약 및 소화기계약으로 사용되어 오고 있다. 갯방풍의 학술연구로서 이전에 발표된 상당수 연구들의 경우, 갯방풍의 주된 약용부위인 뿌리로부터 주로 coumarin, polyacetylnene, lignan, monoterpenoid류에 속하는 성분들이 보고되었으며, 주요 약리활성으로 항산화, 항염증, 항미생물 활성이 보고된 바 있다. 반면 그외의 부위의 경우, 갯방풍 열매와 전초를 대상으로 한 최근 연구를 통해 monoterpenoid, alkyl glycoside, aromatic glycoside 및 pyranocoumarin류 등의 존재가 보고된 바 있다.Meanwhile, Glehnia littoralis Fr. Schm.) is a perennial plant belonging to the mountain type (Umbelliferae). It is a medicinal plant that grows on sandy beaches of Korea and is distributed in Japan, Manchuria, and China. Its roots are called Buksasam, Binbangpung or Liberation Wind, and the effects of Yangeum, Chungcheong, Geodam, and Jihae Therefore, it has been traditionally used as an anti-inflammatory, antitussive agent and digestive contract. In the case of a number of studies previously published as an academic study of Gaetbangpung, components mainly belonging to coumarin, polyacetylnene, lignan, and monoterpenoids have been reported from the roots, which are the main medicinal sites of Gaetbangpung, and have major pharmacological activities such as antioxidant, anti-inflammatory, and anti-inflammatory properties. Microbial activity has been reported. On the other hand, in other sites, the recent studies of Gaetbang wind fruit and outpost have reported the presence of monoterpenoid, alkyl glycoside, aromatic glycoside, and pyranocoumarins.
갯방풍에는 인체에 유익한 성분이 전초에 풍부하게 들어있고, 특히 뿌리에 약효성분이 좀 더 많이 함유되어 있어서 뿌리부분도 이용하는 것이 바람직하나, 뿌리는 경엽보다 쓴맛이 강하여 이를 그대로 섭취하거나 식품에 첨가할 경우 취식자의 거부감을 유발할 수 있으며, 또한 뿌리의 유용성분을 물로 추출하는 경우 장시간이 소요되고 유용성분의 추출량이 적으며, 뿌리의 유용성분은 섭취 시 인체에 흡수되는 비율이 낮은 문제가 있다.Gaetbangpung contains a lot of beneficial ingredients for the human body in the outpost, and it is preferable to use the root part because it contains more medicinal ingredients in the root, but the root has a stronger bitter taste than foliage, so it can be consumed as it is or added to food. In this case, it may cause a feeling of rejection of the ingested person, and also, when extracting the useful component of the root with water, it takes a long time and the extraction amount of the useful component is small, and the useful component of the root has a problem of low absorption rate to the human body when ingested.
상기와 같이 천연의 인체유용성분을 다량 함유하고 있는 갯방풍은 지금까지 주로 약효가 강한 뿌리를 한약재로 이용하여 왔으며, 줄기나 잎은 특별한 가공 없이 단순히 섭취하는 형태로 이용되고 있다. 현재 식약처 원료 등록 현황에서 갯방풍은 어린잎자루를 식용으로 허용하고 있어 잎 부위의 성분과 기능성 규명이 필요하나, 이에 대한 연구는 거의 이루어지지 않고 있는 실정이다. As described above, Gaetbangpung, which contains a large amount of natural human useful ingredients, has been mainly used as a medicinal herb with strong medicinal roots, and stems and leaves are used in a form that is simply consumed without special processing. In the current state of registration of raw materials from the Ministry of Food and Drug Safety, Gaetbangpung permits young petiole for edible use, so it is necessary to identify the components and functional properties of the leaves, but little research has been done on this.
따라서, 본 발명은 상기와 같은 문제점을 해결하기 위하여 안출된 것으로서, 본 발명의 해결하고자 하는 과제는 인체에 부작용이 없으면서 항산화 또는 항균 작용이 우수한 천연물인 갯방풍 잎 에탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 포함하는 조성물을 제공하는 것이다. Therefore, the present invention was devised to solve the above problems, and the problem to be solved of the present invention is that the ethyl acetate fraction of Gaetbangpung leaf ethanol extract, which is a natural product having excellent antioxidant or antibacterial activity, has no side effects on the human body. It is to provide a composition comprising.
구체적으로, 본 발명의 해결하고자 하는 과제는 본 발명은 그람 양성 및 음성 세균을 포함하는 식중독 세균에 대한 항균활성이 우수하고, 인체에 대한 부작용 없이 안전하면서 뛰어나 항산화 활성을 갖는 갯방풍 잎 에탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 포함하는 조성물을 제공하는 것이다. Specifically, the problem to be solved of the present invention is that the present invention is excellent in antimicrobial activity against food poisoning bacteria including gram-positive and negative bacteria, and is safe and excellent without side effects on the human body. It is to provide a composition comprising an ethyl acetate fraction as an active ingredient.
다만, 본 발명에서 이루고자 하는 기술적 과제들은 이상에서 언급한 기술적 과제들로 제한되지 않으며, 언급하지 않은 또 다른 기술적 과제들은 아래의 기재로부터 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 명확하게 이해될 수 있을 것이다.However, the technical problems to be achieved in the present invention are not limited to the technical problems mentioned above, and other technical problems that are not mentioned are clearly apparent to those skilled in the art from the following description. Will be understandable.
상기한 기술적 과제를 달성하기 위하여, 본 발명은 갯방풍 잎 에탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 포함하는 항균 및 항산화 조성물을 제공한다. In order to achieve the above technical problem, the present invention provides an antibacterial and antioxidant composition comprising an ethyl acetate fraction of ethanol extract of Gaetbangpung leaf as an active ingredient.
일 실시예에서, 상기 분획물은 캠프페롤 3-O-β-루티노사이드(Kaempferol 3-O-β-rutinoside), 시나린(Cynarin), 스피레오시드(Spiraeoside) 및 푸푸린(Purpurin)을 함유할 수 있다.In one embodiment, the fraction contains camperol 3-O-β-rutinoside, Cynarin, Spiraeoside and Purpurin can do.
일 실시예에서, 상기 갯방풍 잎 에탄올 추출물은 70중량% 에탄올 용매로 추출할 수 있다.In one embodiment, the ethanol extract of Gaetbangpung leaf can be extracted with a 70% by weight ethanol solvent.
일 실시예에서, 상기 에틸아세테이트 분획물은 바실러스세레우스(B. cereus), 황색포도상구균(S. aureus), 리스테리아(L. monocytogenes), 클로스트리디움 퍼프린젠스(C. perfringens), 살모넬라 타이피뮤리움(S. Typhimurium), 대장균(E. coli), 장염비브리오(V. parahaemolyticus), 캠필로박터 제주니(C. jejuni), 및 캠필로박터 콜리(C. coli)의 저해 활성을 갖는 것일 수 있다.In one embodiment, the ethyl acetate fraction is Bacillus cereus ( B. cereus ), Staphylococcus aureus ( S. aureus ), Listeria ( L. monocytogenes ), Clostridium perfringens ( C. perfringens ), Salmonella typhimurium It may have an inhibitory activity of S. Typhimurium, E. coli , V. parahaemolyticus , C. jejuni , and C. coli .
일 실시예에서, 상기 에틸아세테이트 분획물은 총 폴리페놀 함량이 102.15±0.53 μg GAE/mg이고, 총 플라보노이드 함량이 219.73±0.76 μg CE/mg일 수 있다.In one embodiment, the ethyl acetate fraction may have a total polyphenol content of 102.15±0.53 μg GAE/mg and a total flavonoid content of 219.73±0.76 μg CE/mg.
일 실시예에서, 상기 에틸아세테이트 분획물은 Reducing power (Oyaizu방법)는 0.14±0.00 EC50 mg/mL이고, DPPH radical 소거활성(Riaz Blois방법)은 95.75±0.15%이고, TAC (Harisa방법)은 936.37±18.33 CRE이고, FRAP (Boufadi방법)은 89839.08±283.46 μM일 수 있다.In one embodiment, the ethyl acetate fraction has a reducing power (Oyaizu method) of 0.14±0.00 EC 50 mg/mL, DPPH radical scavenging activity (Riaz Blois method) of 95.75±0.15%, and TAC (Harisa method) of 936.37. ±18.33 CRE, FRAP (Boufadi method) may be 89839.08±283.46 μM.
본 발명에 따른 항균 및 항산화 조성물은 항산화 효과가 우수하고, 식중독(food poisoning) 등의 원인균에 대한 생장 저해 활성이 우수한 특징을 지니므로, 산화 작용 및 미생물 감염에 의해 유발되는 질환의 예방, 개선 또는 치료를 위한 식품 및 의약품 등에 유용하게 이용될 수 있다.The antimicrobial and antioxidant composition according to the present invention has excellent anti-oxidant effect, and has excellent characteristics of growth inhibitory activity against causative bacteria such as food poisoning, and thus prevents, improves or prevents diseases caused by oxidative action and microbial infection or It can be usefully used for food and medicine for treatment.
또한, 본 발명에 따른 항균 및 항산화 조성물은 항산화 및 항균활성으로 인해 각종 식품의 저장기간을 연장하고, 섭취자의 건강유지를 돕는 것은 물론 각종 식품의 기호도를 높이는 효과가 있다.In addition, the antimicrobial and antioxidant composition according to the present invention has the effect of extending the storage period of various foods due to its antioxidant and antibacterial activity, helping to maintain the health of the intake, as well as increasing the preference of various foods.
다만, 본 발명에서 얻을 수 있는 효과는 이상에서 언급한 효과들로 제한되지 않으며, 언급하지 않은 또 다른 효과들은 아래의 기재로부터 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 명확하게 이해될 수 있을 것이다.However, the effects obtainable in the present invention are not limited to the above-mentioned effects, and other effects not mentioned will be clearly understood by those skilled in the art from the following description. Will be able to.
아래에서는 첨부한 도면을 참고로 하여 본 발명의 실시예에 대하여 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 상세히 설명한다. 그러나 본 발명에 관한 설명은 구조적 내지 기능적 설명을 위한 실시예에 불과하므로, 본 발명의 권리범위는 본문에 설명된 실시예에 의하여 제한되는 것으로 해석되어서는 아니 된다. 즉, 실시예는 다양한 변경이 가능하고 여러 가지 형태를 가질 수 있으므로 본 발명의 권리범위는 기술적 사상을 실현할 수 있는 균등물들을 포함하는 것으로 이해되어야 한다. 또한, 본 발명에서 제시된 목적 또는 효과는 특정 실시예가 이를 전부 포함하여야 한다거나 그러한 효과만을 포함하여야 한다는 의미는 아니므로, 본 발명의 권리범위는 이에 의하여 제한되는 것으로 이해되어서는 아니 될 것이다.Hereinafter, exemplary embodiments of the present invention will be described in detail with reference to the accompanying drawings so that those skilled in the art to which the present invention pertains may easily practice. However, since the description of the present invention is only an example for structural or functional description, the scope of the present invention should not be interpreted as being limited by the examples described in the text. That is, since the embodiments can be variously changed and have various forms, it should be understood that the scope of the present invention includes equivalents capable of realizing technical ideas. In addition, the purpose or effect presented in the present invention does not mean that a specific embodiment should include all of them or only such an effect, and the scope of the present invention should not be understood as being limited thereby.
본 발명에서 서술되는 용어의 의미는 다음과 같이 이해되어야 할 것이다.The meaning of the terms described in the present invention should be understood as follows.
"제1", "제2" 등의 용어는 하나의 구성요소를 다른 구성요소로부터 구별하기 위한 것으로, 이들 용어들에 의해 권리범위가 한정되어서는 아니 된다. 예를 들어, 제1 구성요소는 제2 구성요소로 명명될 수 있고, 유사하게 제2 구성요소도 제1 구성요소로 명명될 수 있다. 어떤 구성요소가 다른 구성요소에 "연결되어" 있다고 언급된 때에는, 그 다른 구성요소에 직접적으로 연결될 수도 있지만, 중간에 다른 구성요소가 존재할 수도 있다고 이해되어야 할 것이다. 반면에, 어떤 구성요소가 다른 구성요소에 "직접 연결되어" 있다고 언급된 때에는 중간에 다른 구성요소가 존재하지 않는 것으로 이해되어야 할 것이다. 한편, 구성요소들 간의 관계를 설명하는 다른 표현들, 즉 "~사이에"와 "바로 ~사이에" 또는 "~에 이웃하는"과 "~에 직접 이웃하는" 등도 마찬가지로 해석되어야 한다.Terms such as "first" and "second" are for distinguishing one component from other components, and the scope of rights should not be limited by these terms. For example, the first component may be referred to as the second component, and similarly, the second component may also be referred to as the first component. When a component is said to be "connected" to another component, it should be understood that other components may exist in the middle, although they may be directly connected to the other component. On the other hand, when a component is said to be "directly connected" to another component, it should be understood that no other component exists in the middle. On the other hand, other expressions describing the relationship between the components, that is, "between" and "immediately between" or "neighboring to" and "directly neighboring to" should be interpreted similarly.
단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한 복수의 표현을 포함하는 것으로 이해되어야 하고, "포함하다" 또는 "가지다" 등의 용어는 설시된 특징, 숫자, 단계, 동작, 구성요소, 부분품 또는 이들을 조합한 것이 존재함을 지정하려는 것이며, 하나 또는 그 이상의 다른 특징이나 숫자, 단계, 동작, 구성요소, 부분품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.Singular expressions are to be understood to include plural expressions unless the context clearly indicates otherwise, and terms such as "comprises" or "have" include the features, numbers, steps, actions, components, parts or components described. It is to be understood that a combination is intended to be present, and should not be understood as pre-excluding the existence or addition possibility of one or more other features or numbers, steps, actions, components, parts or combinations thereof.
여기서 사용되는 모든 용어들은 다르게 정의되지 않는 한, 본 발명이 속하는 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가진다. 일반적으로 사용되는 사전에 정의되어 있는 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 것으로 해석되어야 하며, 본 발명에서 명백하게 정의하지 않는 한 이상적이거나 과도하게 형식적인 의미를 지니는 것으로 해석될 수 없다.All terms used herein have the same meaning as generally understood by a person skilled in the art to which the present invention pertains, unless otherwise defined. The terms defined in the commonly used dictionary should be interpreted to be consistent with meanings in the context of related technologies, and cannot be interpreted as having ideal or excessively formal meanings unless explicitly defined in the present invention.
본 발명의 항균 및 항산화 조성물은 갯방풍 잎 에탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 포함한다. The antimicrobial and antioxidant composition of the present invention includes an ethyl acetate fraction of ethanol extract of Gaetbangpung leaf as an active ingredient.
상기 에탄올을 이용한 추출방법으로는 진탕추출, 속슬렛(Soxhlet) 추출 또는 환류 추출을 이용하는 것이 바람직하나 이에 한정되지 않는다. 상기 메탄올을 세척, 건조 및 분말화 한 갯방풍 잎 분량에 1 내지 10배 첨가하여 추출하는 것이 바람직하다. 추출온도는 20℃ 내지 100℃ 인 것이 바람직하고, 20℃ 내지 60℃인 것이 더욱 바람직하고, 50℃인 것이 가장 바람직하나, 이에 한정하지 않는다. 또한, 추출시간은 4 내지 24시간인 것이 바람직하며, 5 내지 12시간인 것이 더욱 바람직하고, 6시간인 것이 가장 바람직하나, 이에 한정하지 않는다. 아울러, 추출 횟수는 1 내지 5회인 것이 바람직하며, 2 내지 4회 반복 추출하는 것이 더욱 바람직하고, 3회인 것이 가장 바람직하나, 이에 한정되는 것은 아니다. 이때, 에탄올은 70중량%인 것이 바람직하다.As the extraction method using ethanol, it is preferable to use shaking extraction, Soxhlet extraction, or reflux extraction, but is not limited thereto. It is preferable to extract the methanol by adding 1 to 10 times to the amount of washed, dried, and powdered leaves. The extraction temperature is preferably 20°C to 100°C, more preferably 20°C to 60°C, and most preferably 50°C, but is not limited thereto. In addition, the extraction time is preferably 4 to 24 hours, more preferably 5 to 12 hours, and most preferably 6 hours, but is not limited thereto. In addition, the number of extractions is preferably 1 to 5 times, more preferably 2 to 4 repetitions, and 3 times is most preferred, but is not limited thereto. At this time, ethanol is preferably 70% by weight.
상기 에탄올 추출물은 여과한 후, 감압농축하여 건조하는 단계를 추가로 포함할 수 있다. 감압농축은 진공감압농축기 또는 진공회전증발기를 이용하는 것이 바람직하나 이에 한정하지 않는다. 또한, 건조는 감압건조, 진공건조, 비등건조, 분무건조 또는 동결건조하는 것이 바람직하나 이에 한정하지 않는다.The ethanol extract may further include a step of filtration, concentration under reduced pressure, and drying. It is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator, but it is not limited to this. In addition, the drying is preferably dried under reduced pressure, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.
상기 에탄올 추출물을 물에 현탁시킨 후 에틸아세테이트로 추출한 분획물은 얻는다. 상기 분획 과정은 1 내지 5회, 바람직하게는 3회 반복하여 수득할 수 있고, 분획 후 감압 농축하는 것이 바람직하나 이에 한정하지 않는다. After the ethanol extract was suspended in water, a fraction extracted with ethyl acetate is obtained. The fractionation process may be obtained by repeating 1 to 5 times, preferably 3 times, and it is preferable to concentrate under reduced pressure after fractionation, but is not limited thereto.
본 발명에 따른 갯방풍 잎 에탄올 추출물의 에틸아세테이트 분획물을 분리하여 함유 물질을 규명한 결과, 캠프페롤 3-O-β-루티노사이드(Kaempferol 3-O-β-rutinoside), 시나린(Cynarin), 스피레오시드(Spiraeoside) 및 푸푸린(Purpurin)을 함유한다는 것을 확인하였다. The ethylacetate fraction of the ethanol extract of Gaetbangpung leaf according to the present invention was separated to identify the contained substance, and as a result, camperol 3-O-β-rutinoside (Kaempferol 3-O-β-rutinoside), cinnarin (Cynarin) , It was confirmed that it contains Spiraeoside and Purpurin.
본 발명의 용어 "항산화"는 산화를 억제하는 작용을 의미하는 것으로, 인체는 산화촉진물질(prooxidant)과 산화억제물질(antioxidant)이 균형을 이루고 있으나 여러 가지 요인들에 의하여 이런 균형상태가 불균형을 이루게 되고 산화촉진 쪽으로 기울게 되면, 산화적 스트레스(oxidative stress)가 유발되어 잠재적인 세포손상 및 병리적 질환을 일으키게 된다. 이러한 산화적 스트레스의 직접적 원인이 되는 활성산소종(reactive oxygen species, ROS)은 불안정하고 반응성이 높아 여러 생체물질과 쉽게 반응하고, 체내 고분자들을 공격하여 세포와 조직에 비가역적인 손상을 일으키거나 돌연변이, 세포독성 및 발암 등을 초래하게 된다. NO, HNO2, ONOO-와 같은 활성질소종(reactive nitrogen species, RNS)은 염증 반응 시 대식세포 호중구 및 다른 면역 세포 들의 면역반응으로 인해 다량 생성되며, 이때 ROS도 같이 생성된다. 상기와 같은 활성산소는 체내에서 세포를 산화시켜 파괴시키며, 그에 따라 각종 질환에 노출되게 된다. The term "antioxidant" of the present invention refers to an action of inhibiting oxidation, and the human body has a balance of an oxidizing accelerator (prooxidant) and an antioxidant (antioxidant). When it is achieved and tilted toward the oxidative acceleration, oxidative stress is induced, causing potential cell damage and pathological diseases. Reactive oxygen species (ROS), which are the direct cause of these oxidative stresses, are unstable and highly reactive, so they can easily react with various biological materials, attack polymers in the body, and irreversibly damage or mutate cells and tissues. It causes cytotoxicity and carcinogenesis. Reactive nitrogen species (RNS) such as NO, HNO 2 and ONOO - are produced in large quantities due to the immune response of macrophage neutrophils and other immune cells during an inflammatory reaction, and ROS is also generated. The free radicals as described above oxidize and destroy cells in the body, and thus are exposed to various diseases.
본 발명의 구체적인 실시예에서 갯방풍 잎 에탄올 추출물의 에틸아세테이트 분획물의 항산화 효과를 확인하기 위하여 Reducing power, DPPH (2,2-diphenyl-1-picrylhydrazyl) radical 소거활성 측정, TAC (total antioxidant capacity) 및 FRAP (ferric reducing antioxidant potential) value 측정을 수행한 결과, 강한 항산화 효과를 나타낸다는 것을 확인하였다. 또한, 총 폴리페놀 함량 및 총 플라보노이드 함량도 우수하다는 것을 확인하였다.Reducing power, DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging activity measurement, TAC (total antioxidant capacity) and to confirm the antioxidant effect of ethyl acetate fraction of ethanol extract of Gaetbangpung leaf in a specific embodiment of the present invention As a result of measuring the FRAP (ferric reducing antioxidant potential) value, it was confirmed that it shows a strong antioxidant effect. In addition, it was confirmed that the total polyphenol content and the total flavonoid content are also excellent.
또한, 본 발명의 용어 "항균"은 세균이나 진균 등의 미생물의 생장 및 증식을 억제 또는 제어하는 작용을 의미하는 것으로, 본 발명의 미생물은 이에 제한되지는 않으나, 바실러스세레우스(B. cereus), 황색포도상구균(S. aureus), 리스테리아(L. monocytogenes), 클로스트리디움 퍼프린젠스(C. perfringens), 살모넬라 타이피뮤리움(S. Typhimurium), 대장균(E. coli), 장염비브리오(V. parahaemolyticus), 캠필로박터 제주니(C. jejuni), 및 캠필로박터 콜리(C. coli)일 수 있다. In addition, the term "antibacterial" of the present invention refers to the action of inhibiting or controlling the growth and proliferation of microorganisms such as bacteria and fungi, the microorganism of the present invention is not limited thereto, but Bacillus cereus ( B. cereus ) , Staphylococcus aureus (S. aureus), Listeria (L. monocytogenes), Clostridium perfringens (C. perfringens), S. typhimurium (S. typhimurium), Escherichia coli (E. coli), Vibrio (V there can be parahaemolyticus), Campylobacter your Jeju (C. jejuni), and Campylobacter coli (C. coli).
본 발명의 구체적인 실시예에서 갯방풍 잎 에탄올 추출물의 에틸아세테이트 분획물의 항균 효과를 확인하기 위하여 상기 균주들에 대한 항균 활성을 특정한 결과, 상기 균주에서 생장 저해 활성이 우수하다는 것을 확인하였다. In a specific embodiment of the present invention, in order to confirm the antibacterial effect of the ethyl acetate fraction of the ethanol extract of Gaetbangpung leaf, it was confirmed that the antibacterial activity against the strains was excellent, and the growth inhibition activity in the strain was excellent.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 범주 및 기술사상 범위내에서 다양한 변경 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다.Hereinafter, preferred examples are provided to help understanding of the present invention, but the following examples are merely illustrative of the present invention, and it is apparent to those skilled in the art that various changes and modifications are possible within the scope and technical scope of the present invention. It is also natural that such modifications and modifications fall within the scope of the appended claims.
실시예 1 : 갯방풍 잎 추출물의 분획물 제조Example 1: Preparation of the fraction of Gaetbangpung leaf extract
갯방풍 어린 잎을 동결건조 하여 분말한 후 70% 에탄올(EE)을 가하여 추출·여과한 후, n-헥산(n-hexane, HF), 에틸아세테이트(ethylacetate, EAF), 부탄올(butanol, BF), 물(H2O, WF)로 용매의 극성도를 높여가며 순차적으로 분획하여 분획물을 제조하였다.Freeze-dried young leaves of Gaetbangpung, then extract and filter with 70% ethanol (EE), n-hexane (HF), ethylacetate (EAF), butanol (BF) , Fractions were prepared by sequentially sequencing while increasing the polarity of the solvent with water (H 2 O, WF).
실험예 1 : 식중독균 저해활성Experimental Example 1: Food poisoning bacteria inhibitory activity
디스트 확산 방법(Disc diffusion method)을 사용하여 항균활성을 측정하였다. 이때, disc는 6 mm를 사용하였으며, 각 추출물의 분획물 농도는 100 μg/disc로 하여 수행하였다.Antibacterial activity was measured using the Disc diffusion method. At this time, a disc of 6 mm was used, and the fraction concentration of each extract was performed at 100 μg/disc.
microorganismIndicator
microorganism
1ND, not detected (inhibition zones with values ≤7 mm were assumed as being absent of antimicrobial activity).Data are mean ± SD ( n = 3).
1 ND, not detected (inhibition zones with values ≤7 mm were assumed as being absent of antimicrobial activity).
상기 표 1은 갯방풍 잎 에탄올 추출물의 각 용매 분획물의 식중독 세균 9종에 대한 항균 활성을 확인한 결과를 나타낸 것이다. 상기 각 용매의 분획물은 그람 양성 및 음성 세균에 대하여 모두 활성을 나타낸다는 것을 확인할 수 있으며, 특히, L. monocytogenes에 대해서는 가장 강한 활성을 나타내었다. Table 1 shows the results of confirming the antimicrobial activity of nine food poisoning bacteria of each solvent fraction of the ethanol extract of Gaetbangpung leaf. It can be seen that the fractions of each solvent show activity against both Gram-positive and negative bacteria, and in particular, showed the strongest activity against L. monocytogenes .
이중, 갯방풍 잎 에탄올 추출물의 에틸아세테이트 분획물은 모든 그람 양성 및 음성 세균에 대하여 강한 활성을 나타내었다.Among them, the ethyl acetate fraction of ethanol extract from Gaetbangpung leaves showed strong activity against all Gram positive and negative bacteria.
실험예 2 : 항산화 활성Experimental Example 2: Antioxidant activity
1) 항산화 물질 함량 측정1) Measurement of antioxidant content
갯방풍 잎 에탄올 추출물의 분획물의 총 폴리페놀 함량(Total polyphenolic content) 및 총 플라보노이드 함량(Total flavonoid content)을 측정하였다. The total polyphenolic content and total flavonoid content of the fractions of the ethanol extract of Gaetbangpung leaf were measured.
총 폴리페놀 함량은 Folin-Ciocalteu 방법 (Dewanto, Wu, Adom, and Liu, 2002)을 사용하여 분석하였다. 시료 200 μL에 5 mL Folin-Ciocalteu's reagent (Sigma Co., St. Louis, MO)을 첨가하여 산화시킨 후. 5% 소듐 카보네이트(sodium carbonate) 3 mL을 가하여 중화하였다. 이후에 암소의 실온에서 30 분 배양 후, 725 nm에서 각 샘플의 흡광도를 측정하였다. 표준곡선은 gallic acid (Sigma Co.)를 이용하여 검량곡선을 작성한 후 함량 계산에 활용하였다. Total polyphenol content was analyzed using the Folin-Ciocalteu method (Dewanto, Wu, Adom, and Liu, 2002). After oxidation by adding 5 mL Folin-Ciocalteu's reagent (Sigma Co., St. Louis, MO) to 200 μL of the sample. Neutralize by adding 3 mL of 5% sodium carbonate. Thereafter, after 30 minutes of incubation at room temperature in the cow, the absorbance of each sample was measured at 725 nm. The standard curve was used to calculate the content after preparing a calibration curve using gallic acid (Sigma Co.).
총 플라보노이드 함량은 비색법(Dewanto, Wu, Adom, and Liu, 2002)을 사용하여 분석하였다. 시료 500 μL를 5% NaNO2 75 μL와 혼합하고 실온에서 5 분간 반응한다. 이후 10% AlCl3·6H2O 150 μL를 혼합물에 첨가 한 다음 1 M NaOH 0.5 mL와 탈 이온수 275 μL를 넣었다. 샘플의 흡광도를 510 nm에서 측정 하였다. 총 플라보노이드 함량은 샘플 mg 당 μg 카테킨 당량(CE)으로 표현되었다.Total flavonoid content was analyzed using a colorimetric method (Dewanto, Wu, Adom, and Liu, 2002). 500 μL of sample is mixed with 75 μL of 5% NaNO 2 and reacted for 5 minutes at room temperature. Then, 150 μL of 10% AlCl 3 ·6H 2 O was added to the mixture, followed by 0.5 mL of 1 M NaOH and 275 μL of deionized water. The absorbance of the sample was measured at 510 nm. Total flavonoid content was expressed in μg catechin equivalent (mg) per mg sample.
(μg GAE1/mg)Total polyphenolic content
(μg GAE 1 /mg)
(μg CE2/mg)Total flavonoid content
(μg CE 2 /mg)
a-e Different letters within a column differ significantly, based on Duncan’s multiple-range test (P < 0.05).
1: Presented as the number of μg GAE (gallic acid equivalent).
2: Presented as the number of μg CE (catechin equivalent).Data are shown as the mean ± SD (n = 3).
ae Different letters within a column differ significantly, based on Duncan's multiple-range test (P <0.05).
1 : Presented as the number of μg GAE (gallic acid equivalent).
2 : Presented as the number of μg CE (catechin equivalent).
상기 표 2와 같이, 갯방풍 잎 에탄올 추출물의 에틸아세테이트 분획물의 총 폴리페놀 함량은 다른 용매 분획물에 비해 2 내지 10배 이상으로 높다는 것을 확인할 수 있다. 또한, 에틸아세테이트 분획물의 총 플라보노이드 함량 역시 다른 용매 분획물에 비해 우수하다는 것을 확인할 수 있었다. As shown in Table 2 above, it can be seen that the total polyphenol content of the ethyl acetate fraction of the ethanol extract of Gaetbangpung leaf is 2 to 10 times higher than that of other solvent fractions. In addition, it was confirmed that the total flavonoid content of the ethyl acetate fraction was also superior to other solvent fractions.
2) 항산화 활성 측정2) Antioxidant activity measurement
항산화 활성 측정은 하기의 4가지 방법을 사용하여 측정하였다.The antioxidant activity was measured using the following four methods.
[측정방법][How to measure]
① Reducing power :Oyaizu 방법 ① Reducing power: Oyaizu method
② DPPH (2,2-diphenyl-1-picrylhydrazyl) radical 소거활성 측정: Blois 방법② DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging activity measurement: Blois method
③ TAC (total antioxidant capacity): Harisa 방법③ TAC (total antioxidant capacity): Harisa method
④ FRAP (ferric reducing antioxidant potential) value 측정: Boufadi 방법④ FRAP (ferric reducing antioxidant potential) value measurement: Boufadi method
(%)DPPH
(%)
CRE1 (μM)TAC
CRE 1 (μM)
FIE2 (μM)FRAP
FIE 2 (μM)
a-e Different letters within a column differ significantly, based on Duncan’s multiple-range test (P < 0.05).
1 Copper reducing equivalent.
2 Fe2 + iron equivalent. Data are shown as the mean ± SD (n = 3).
ae Different letters within a column differ significantly, based on Duncan's multiple-range test (P <0.05).
1 Copper reducing equivalent.
2 Fe 2 + iron equivalent.
상기 표 3과 같이, 갯방풍 잎 에탄올 추출물의 에틸아세테이트 분획물의 4가지 항산화 활성이 다른 용매 분획물에 비해 우수하며, 상용화 되는 ascorbic acid와 비교 시에도 Reducing power 및 DPPH 활성이 더 뛰어난 것으로 확인할 수 있었다. As shown in Table 3, it was confirmed that the four antioxidant activities of ethyl acetate fraction of Gaetbangpung leaf ethanol extract are superior to other solvent fractions, and the reducing power and DPPH activity are superior even when compared with commercially available ascorbic acid.
실험예 3: 세포독성 평가 (in vitro) Experimental Example 3: Cytotoxicity evaluation (in vitro)
간암세포인 HepG2 cell을 이용한 CCK-8 assay 수행하여 세포독성을 평가하였다. 이때, 24시간 동안 처리된 셀의 Cell density는 5×104 이고 샘플(각 용매의 분획물)은 50, 100, 200, 400 μg/mL농도로, 24시간 동안 처리하였으며, CCK-8 시약을 4시간동안 처리하였다. Cytotoxicity was evaluated by performing a CCK-8 assay using HepG2 cell, a liver cancer cell. At this time, the cell density of the cell treated for 24 hours is 5×10 4 and the sample (a fraction of each solvent) is treated at a concentration of 50, 100, 200, 400 μg/mL for 24 hours, and the CCK-8 reagent is 4 Treated for hours.
상기 표 4에 나타낸 바와 같이, 갯방풍 잎 에탄올 추출물의 에틸아세테이트 추출물의 세포독성은 400 μg/mL 농도에서 70% 이상의 생존율을 나타냈으며, 식중독균 제어 농도 100 μg/mL에서는 90% 이상의 세포 생존율을 나타내었다.As shown in Table 4, the cytotoxicity of the ethyl acetate extract of the ethanol extract of Gaetbangpung leaf showed a survival rate of 70% or more at a concentration of 400 μg/mL, and a cell survival rate of 90% or more at a concentration of 100 μg/mL of food poisoning control. Did.
실시예Example 2 : 갯방풍 잎 에탄올 추출물의 에틸아세테이트 2: Ethyl Acetate of Gaetbangpung Leaf Ethanol Extract 분획물의Fraction 주요 화합물 4종 규명 Identification of 4 major compounds
건조한 갯방풍 잎(500 g)을 블랜더로 곱게 갈아 70% 에탄올에서 24시간씩 3회 추출하였다. 그런 다음 상기 70% 에탄올 추출물을 감압 농축하고 70% 에탄올 농축물을 얻었다. 이 농축물을 500 mL 증류수에 녹인 후, 극성이 낮은 용매 순(n-Hexane, Ethyl acetate, Butanol, Water)으로 액체-액체 추출(3회, 1:1(v:v)) 하였다. 각각의 추출된 용매층을 모아 감압 농축하였으며 이 중 Ethyl acetate 분획물을 사용하여 분석하였다.Dry gyebangpung leaves (500 g) were finely ground with a blender and extracted three times for 24 hours in 70% ethanol. Then, the 70% ethanol extract was concentrated under reduced pressure to obtain a 70% ethanol concentrate. After dissolving the concentrate in 500 mL of distilled water, liquid-liquid extraction (3 times, 1:1 (v:v)) was performed with a low-polarity solvent (n-Hexane, Ethyl acetate, Butanol, Water). Each extracted solvent layer was collected, concentrated under reduced pressure, and analyzed using Ethyl acetate fraction.
갯방풍 Ethyl acetate 분획물 분석은 초고성능액체크로마토그래피(UPLC) 시스템을 사용하여 수행되었다. 분리는 Acquity UPLC HSS T3 컬럼(100 mm × 2.1 mm, 1.8 ㎛, Waters)을 사용하여 컬럼온도 40℃ 그리고 유속 0.5 mL/min으로 사용하였다. 이동상은 용매 A(물 + 0.1% 포름산) 과 용매 B (acetonitrile + 0.1% 포름산)을 사용하였다. 용매 조성비는 0 내지 5 min(용매 A 97%), 5 내지 16 min(용매 B, 3 내지 100% liner gradient), 16 내지 17 min(용매 B 100%), 17 내지 19 min(3 내지 100% reverse liner gradient 용매 B), 19 내지 25 min(97% 용매 A)였고 각 샘플의 5 μL 주입하였다. 컬럼에서 용리된 물질은 high-resolution tandem mass spectrometer SYNAPT G2 Si HDMS QTOF (Waters) 장비의 positive 와 negative ion mode로 분석되었다. positive mode에서 capillary voltage 2 kV와 cone voltage 40 V였고, negative mode에서 capillary voltage 1 kV와 cone voltage 40 V으로 사용하였다. 스캔 범위는 50 내지 1200 Da이였고 스캔 시간은 0.2 s였다.Ethyl acetate fraction analysis of Gaetbangpung was performed using an ultra high performance liquid chromatography (UPLC) system. Separation was performed using an Acquity UPLC HSS T3 column (100 mm×2.1 mm, 1.8 μm, Waters) at a column temperature of 40° C. and a flow rate of 0.5 mL/min. As the mobile phase, solvent A (water + 0.1% formic acid) and solvent B (acetonitrile + 0.1% formic acid) were used. The solvent composition ratio is 0 to 5 min (solvent A 97%), 5 to 16 min (solvent B, 3 to 100% liner gradient), 16 to 17 min (solvent B 100%), 17 to 19 min (3 to 100%) reverse liner gradient solvent B), 19-25 min (97% solvent A) and injected 5 μL of each sample. The material eluted from the column was analyzed in positive and negative ion mode of a high-resolution tandem mass spectrometer SYNAPT G2 Si HDMS QTOF (Waters) instrument. In positive mode, the capillary voltage was 2 kV and the cone voltage was 40 V, and in the negative mode, the capillary voltage was 1 kV and the cone voltage was 40 V. The scan range was 50 to 1200 Da and the scan time was 0.2 s.
분석된 모든 질량분석 데이터는 상용 소프트웨어인 UNIFI (version 1.71; Waters Corporation, Milford, MA)를 사용하여 크로마토그램 정렬, 피크 피킹, 피크 면적 추출, 표준화를 실시하였다. 정확한 질량분석을 위하여 로이신 엔케팔린(Leucine enkephalin)을 외부표준 물질로 사용하여 실시간 질량 값을 보정하는 방법으로 분석을 진행하였다. All analyzed mass spectrometry data were subjected to chromatogram sorting, peak picking, peak area extraction, and normalization using commercial software UNIFI (version 1.71; Waters Corporation, Milford, MA). For accurate mass spectrometry, Leucine enkephalin was used as an external standard to perform real-time mass value correction.
상기 분석 결과, 하기 4종의 주요 화합물을 확인하였으며, 이의 구조 확인 데이터는 하기 표 5에 나타내었다. As a result of the analysis, the following four main compounds were identified, and their structural confirmation data are shown in Table 5 below.
① 캠프페롤 3-O-β-루티노사이드(Kaempferol 3-O-β-rutinoside) ① Camperol 3-O-β-rutinoside
② 시나린(Cynarin)② Cynarin
③ 스피레오시드(Spiraeoside) ③ Spieoside
④ 푸푸린(Purpurin)④ Purpurin
(g/mol)Molecular Weight
(g/mol)
mass (Da)Neutral
mass (Da)
RT (min)Observed
RT (min)
3-O-β-
rutinosideKaempferol
3-O-β-
rutinoside
실험예 4 : 에틸아세테이트 분획물의 주요 화합물 4종의 항균 활성Experimental Example 4: Antibacterial activity of four major compounds of ethyl acetate fraction
L. monocytogenes , C. perfringens , C. coli 식중독균을 감수성으로 하고 각 4종의 화합물을 10 mM 및 50 mM의 농도로 처리하여 생육 저해환을 측정하였다.Growth inhibition was measured by treating L. monocytogenes , C. perfringens , and C. coli food poisoning bacteria as sensitive and treating each of the four compounds at concentrations of 10 mM and 50 mM.
(Data are shown as the mean ± SD (n = 3))(Data are shown as the mean ± SD (n = 3))
상기 표 6과 같이, 플라보노이드 유도체 화합물 4종은 그람 양성 및 음성 식중독균에 대한 항균활성을 가지며, 이 중 purpurin의 활성이 가장 높았으며, 그 뒤를 이어 spiraeoside, cynarin, kaempferol 3-O-β-rutinoside 순으로 나타남을 확인할 수 있다.As shown in Table 6, the four flavonoid derivative compounds have antibacterial activity against Gram positive and negative food poisoning bacteria, among which purpurin has the highest activity, followed by spiraeoside, cynarin, and kaempferol 3-O-β-rutinoside It can be confirmed that appears.
또한, 화합물의 농도에 따른 항균활성은 3종(spiraeoside, cynarin, kaempferol 3-O-β-rutinoside)의 화합물은 농도에 따른 활성변화가 거의 없으며, purpurin은 50 mM에서 C. perfringens과 C. coli에 대해 높은 활성을 나타내었다.In addition, the antimicrobial activity according to the concentration of the compound is three types (spiraeoside, cynarin, kaempferol 3-O-β-rutinoside), there is little activity change according to the concentration, purpurin is 50 mM C. perfringens and C. coli It showed high activity against.
실험예Experimental Example 5 : 에틸아세테이트 5: ethyl acetate 분획물의Fraction 주요 화합물 4종의 항산화 활성 Antioxidant activity of 4 major compounds
[측정방법][How to measure]
① Reducing power: Oyaizu방법 ① Reducing power: Oyaizu method
② DPPH (2,2-diphenyl-1-picrylhydrazyl) radical 소거활성 측정: Riaz Rajoka방법② DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging activity measurement: Riaz Rajoka method
(mg/mL)DPPH EC 50
(mg/mL)
(Data are shown as the mean ± SD (n = 3))(Data are shown as the mean ± SD (n = 3))
상기 표 7과 같이, 플라보노이드 유도체 화합물의 4종 모두 RP 및 DPPH 실험 결과 항산화 활성을 나타낸다는 것을 확인할 수 있다. RP 결과, cynarin은 가장 높은 항산화 활성을 나타냈으며, 양성 대조군(ascorbic acid)에 비해 높은 활성을 보였다. 또한, DPPH 결과, purpurin이 가장 높은 활성을 보였으며, kaempferol 3-O-β-rutinoside는 RP과 마찬가지로 화합물 4종 중 가장 낮은 항산화 활성을 보임을 확인할 수 있었다.As shown in Table 7, it can be seen that all four of the flavonoid derivative compounds show antioxidant activity as a result of RP and DPPH experiments. As a result of RP, cynarin showed the highest antioxidant activity and higher activity than the positive control (ascorbic acid). In addition, as a result of DPPH, purpurin showed the highest activity, and kaempferol 3-O-β-rutinoside showed the lowest antioxidant activity among the four compounds like RP.
실험예 6 : purpurin의 식중독균 저해활성Experimental Example 6: Purpurin inhibitory activity of food poisoning bacteria
디스트 확산 방법(Disc diffusion method)을 사용하여 항균활성을 측정하였다. 이때, disc는 6 mm를 사용하였으며, 하기 표 8과 같이 purpurin의 농도는 변화시키면서 수행하였다. 대조군으로 항생제 gentamicin을 사용하였다.Antibacterial activity was measured using the Disc diffusion method. At this time, the disc was used 6 mm, it was carried out while changing the concentration of purpurin as shown in Table 8. The antibiotic gentamicin was used as a control.
microorganismIndicator
microorganism
1n.d., not detected (inhibition zones with values ≤7 mm were assumed as being absent of antimicrobial activity).Data are mean ± SD ( n = 3).
1 nd, not detected (inhibition zones with values ≤7 mm were assumed as being absent of antimicrobial activity).
상기 표 8은 갯방풍 잎 에탄올 추출물의 에틸아세테이트 분획물로부터 얻어진 purpurin의 농도 변화에 따른 식중독균 10종에 대한 항균활성을 확인한 결과를 나타낸 것이다. 특히 C. perfringens에 대해서는 강한 활성을 나타내었다. 또한 B . cereus , C. perfringens , C. coli에 대해서는 화학적 항생제인 gentamicin 보다 강한 활성을 나타냈다.Table 8 shows the results of confirming the antibacterial activity against 10 food poisoning bacteria according to the change in purpurin concentration obtained from the ethyl acetate fraction of ethanol extract of Gaetbangpung leaf. In particular, it showed strong activity against C. perfringens . Also B. The cereus , C. perfringens , and C. coli showed stronger activity than the chemical antibiotic gentamicin.
Claims (10)
Ethyl acetate fraction of Gaetbangpung leaf ethanol extract contains as an active ingredient, the fraction is campferol 3-0-β-rutinoside (Kaempferol 3-0-β-rutinoside), cinnarin (Cynarin), spireoside Antioxidant food composition characterized by containing any one of (Spiraeoside) and Purpurin (Purpurin).
The antioxidant food composition of claim 1, wherein the ethanol extract of Gaetbangpung leaf is extracted with a 70% by weight ethanol solvent.
The method according to claim 1, wherein the ethyl acetate fraction is Bacillus cereus (B.cereus), Staphylococcus aureus (S. aureus), Listeria (L. monocytogenes), Clostridium perfringens (C. perfringens), Salmonella typhimurium Antioxidant food characterized by having inhibitory activity of S. Typhimurium, E. coli, V. parahaemolyticus, C. jejuni, and C. coli Composition.
The antioxidant food composition of claim 1, wherein the ethyl acetate fraction has a total polyphenol content of 102.15±0.53 μg GAE/mg and a total flavonoid content of 219.73±0.76 μg CE/mg.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190046775A KR102120005B1 (en) | 2019-04-22 | 2019-04-22 | A composition having anti-oxidation or anti-bacterial activity comprising Glehnia littoralis extracts |
KR1020190132927A KR102290385B1 (en) | 2019-04-22 | 2019-10-24 | A composition having anti-oxidation or anti-bacterial activity comprising Glehnia littoralis extracts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190046775A KR102120005B1 (en) | 2019-04-22 | 2019-04-22 | A composition having anti-oxidation or anti-bacterial activity comprising Glehnia littoralis extracts |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190132927A Division KR102290385B1 (en) | 2019-04-22 | 2019-10-24 | A composition having anti-oxidation or anti-bacterial activity comprising Glehnia littoralis extracts |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102120005B1 true KR102120005B1 (en) | 2020-06-08 |
Family
ID=71089392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190046775A KR102120005B1 (en) | 2019-04-22 | 2019-04-22 | A composition having anti-oxidation or anti-bacterial activity comprising Glehnia littoralis extracts |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102120005B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220042661A (en) * | 2020-09-28 | 2022-04-05 | 한국식품연구원 | A composition for the prevention, improvement or treatment of sleep disorders or insomnia containing Glehnia littoralis extract |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101413363B1 (en) | 2012-08-29 | 2014-07-01 | 조선대학교산학협력단 | Use of Glehnia littoralis extracts for controlling prostaglandin E2 |
KR101610267B1 (en) | 2014-07-22 | 2016-04-07 | 농업회사법인 달맞이식품 유한회사 | Method for Manufacturing Dutch Coffee with Glehnia littoralis |
KR101787566B1 (en) | 2016-05-18 | 2017-10-18 | 목포대학교 산학협력단 | Pharmaceutical composition for preventing or treating of cardiovascular diseases comprising Glehnia littoralis extracts |
KR101867480B1 (en) | 2016-01-20 | 2018-06-14 | 농업회사법인 달맞이식품 유한회사 | Manufacturing method of the extract with Glehnia littoralis for food |
-
2019
- 2019-04-22 KR KR1020190046775A patent/KR102120005B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101413363B1 (en) | 2012-08-29 | 2014-07-01 | 조선대학교산학협력단 | Use of Glehnia littoralis extracts for controlling prostaglandin E2 |
KR101610267B1 (en) | 2014-07-22 | 2016-04-07 | 농업회사법인 달맞이식품 유한회사 | Method for Manufacturing Dutch Coffee with Glehnia littoralis |
KR101867480B1 (en) | 2016-01-20 | 2018-06-14 | 농업회사법인 달맞이식품 유한회사 | Manufacturing method of the extract with Glehnia littoralis for food |
KR101787566B1 (en) | 2016-05-18 | 2017-10-18 | 목포대학교 산학협력단 | Pharmaceutical composition for preventing or treating of cardiovascular diseases comprising Glehnia littoralis extracts |
Non-Patent Citations (2)
Title |
---|
약학회지 제49권 제4호 312 ~ 316, (2005)* * |
한국생물공학회지 제19권 제1호, Vol. 19, No. 1, 57-61, (2004)* * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220042661A (en) * | 2020-09-28 | 2022-04-05 | 한국식품연구원 | A composition for the prevention, improvement or treatment of sleep disorders or insomnia containing Glehnia littoralis extract |
KR102527256B1 (en) | 2020-09-28 | 2023-04-28 | 한국식품연구원 | A composition for the prevention, improvement or treatment of sleep disorders or insomnia containing Glehnia littoralis extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Makni et al. | Citrus limon from Tunisia: Phytochemical and physicochemical properties and biological activities | |
Stanisavljević et al. | Antioxidant and antimicrobial activities of Echinacea (Echinacea purpurea L.) extracts obtained by classical and ultrasound extraction | |
Lee et al. | Polyphenol composition and antioxidant activity from the vegetable plant'Artemisia absinthium'L. | |
Abdelkader et al. | Phytochemical study and biological activity of sage (Salvia officinalis L.) | |
Zdunić et al. | In vitro hypoglycemic, antioxidant and antineurodegenerative activity of chokeberry (Aronia melanocarpa) leaves | |
KR101704874B1 (en) | Cosmetic Compositions with Whitening and Anti-oxidative Effect Comprising of Phragmitis Rhizoma, Salicomia herbacea L. and Prunus mume | |
Bazzaz et al. | Antioxidant and antimicrobial activity of methanol, dichloromethane, and ethyl acetate extracts of Scutellaria litwinowii | |
Gontijo et al. | Antioxidant study indicative of antibacterial and antimutagenic activities of an ellagitannin-rich aqueous extract from the leaves of Miconia latecrenata | |
Xiong et al. | Phytochemical characterization and anti-inflammatory properties of Acacia mearnsii leaves | |
Khalid et al. | Phenolic Profile and Biological Properties of Momordica charantia' | |
Marian et al. | Salivia officinalis L. and Verbascum phlomoides L. chemical, antimicrobial, antioxidant and antitumor investigations | |
Bobasa et al. | Hydrolysable tannins in Terminalia ferdinandiana Exell fruit powder and comparison of their functional properties from different solvent extracts | |
Radhia et al. | Phytochemical screening, antioxidant and antimicrobial activities of Erodium glaucophyllum (L.) L’Hérit | |
Klomsakul et al. | Evaluation of antioxidant activities and tyrosinase inhibitory effects of Ginkgo biloba tea extract | |
Melo et al. | Antioxidant capacity and antimicrobial activity of commercial samples of guava leaves (Psidium guajava) | |
Ferreres et al. | In vitro studies of α-glucosidase inhibitors and antiradical constituents of Glandora diffusa (Lag.) DC Thomas infusion | |
KR102232572B1 (en) | Manufacturing method for cosmetic pomposition comprising centella asiatica extract | |
Zainab et al. | Studies on antioxidant and antimicrobial activities of Pajanelia longifolia (Willd.) Schumann | |
Shinde et al. | Antioxidant activity and antiproliferative action of methanolic extract of liquorice (Glycyrrhiza glabra) in HepG2 cell line | |
KR102120005B1 (en) | A composition having anti-oxidation or anti-bacterial activity comprising Glehnia littoralis extracts | |
KR101244752B1 (en) | Cosmetic ingredient containing whitening, anti-aging, anti-oxidation and anti-microbial activities | |
KR20200138934A (en) | A composition for antioxiation and antiinflammation comprising aronia fermented broth and Reed young leave extract | |
KR20030021640A (en) | Extracts of Phyllostachys edulis leaf having antioxidant activity and the process for preparation thereof | |
Mirzania et al. | Biochemical evaluation of antioxidant activity, phenol and flavonoid contents of dracocephalum kotschyi boiss extracts obtained with different solvents | |
KR102290385B1 (en) | A composition having anti-oxidation or anti-bacterial activity comprising Glehnia littoralis extracts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |